AveXis, Inc.
(NASDAQ : AVXS)

( )
AVXS PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Loading AVXS News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.81%70.660.9%$747.87m
AMGNAmgen Inc.
-1.62%170.851.1%$707.06m
CELGCelgene Corporation
-2.18%130.931.1%$645.79m
REGNRegeneron Pharmaceuticals, Inc.
-2.67%502.122.7%$590.62m
BIIBBiogen Inc.
-3.06%271.251.2%$491.73m
ALXNAlexion Pharmaceuticals, Inc.
-2.38%122.111.9%$450.82m
VRTXVertex Pharmaceuticals Incorporated
-3.13%129.231.9%$271.19m
INCYIncyte Corporation
-3.24%130.312.6%$256.98m
CLVSClovis Oncology, Inc.
-4.76%89.9618.0%$244.46m
TSROTESARO, Inc.
-3.87%141.0314.7%$243.48m
BLUEBluebird Bio, Inc.
-3.78%106.9019.3%$159.98m
ILMNIllumina, Inc.
-2.50%176.363.5%$150.43m
KITEKite Pharma, Inc.
-2.37%98.0516.1%$139.68m
EXASExact Sciences Corporation
-2.43%34.0926.3%$128.59m
AAgilent Technologies, Inc.
-0.63%58.871.5%$122.37m

Company Profile

AveXis, Inc. operates as a clinical-stage gene therapy company that engages in the research and development of technology specifically for neurological genetic disease treatment. Its proprietary gene therapy candidate, AVXS-101 has been granted orphan drug designation for the treatment of all types of spinal muscular atrophy and fast track designation for the treatment of spinal muscular atrophy type 1. The company was founded by John D. Harkey, Jr. in 2010 and is headquartered in Chicago, IL.,0DP17Q-E